Bionano Genomics

Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, and translocations, that can be associated with various genetic disorders and diseases, including cancer.

Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies.

Bionano Genomics headquartered in United States, North America, operates in the Biotechnology, Medical, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $94.1B in funding across 272 round(s). With a team of 251-500 employees, Bionano Genomics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Bionano Genomics, raised $23.3M. Discover more about their projects, partnerships, and impact on our platform.